trending Market Intelligence /marketintelligence/en/news-insights/trending/9wkj_ybc-kbg1onvlsuinw2 content esgSubNav
In This List

Omeros settles patent lawsuit with Lupin regarding eye treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Omeros settles patent lawsuit with Lupin regarding eye treatment

Omeros Corp. said it agreed to settle a patent infringement lawsuit against India's Lupin Ltd regarding a generic version of its eye drug Omidria.

Lupin had filed an application with the U.S. Food and Drug Administration to market a generic version of Omidria in 2017.

Under the settlement, Lupin confirmed the validity of all asserted patents for Omidria, with Oct. 23, 2033 as the last date for the expiration of Omeros' asserted patents.

The terms regarding the market entry of the generic version were similar to Omeros' previous settlement with Endo International PLC, under which a generic cannot be launched before April 1, 2032.

Seattle-based Omeros develops and sells drugs that target inflammation, bleeding disorders and central nervous system disorders.